Journal article icon

Journal article : Review

Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens

Abstract:
Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of invasive infections caused by Aspergillus fumigatus to inform the first FPPL. The pre-specified criteria of mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence were used to search for relevant articles between 1 January 2016 and 10 June 2021. Overall, 49 studies were eligible for inclusion. Azole antifungal susceptibility varied according to geographical regions. Voriconazole susceptibility rates of 22.2% were reported from the Netherlands, whereas in Brazil, Korea, India, China, and the UK, voriconazole susceptibility rates were 76%, 94.7%, 96.9%, 98.6%, and 99.7%, respectively. Cross-resistance was common with 85%, 92.8%, and 100% of voriconazole-resistant A. fumigatus isolates also resistant to itraconazole, posaconazole, and isavuconazole, respectively. The incidence of invasive aspergillosis (IA) in patients with acute leukemia was estimated at 5.84/100 patients. Six-week mortality rates in IA cases ranged from 31% to 36%. Azole resistance and hematological malignancy were poor prognostic factors. Twelve-week mortality rates were significantly higher in voriconazole-resistant than in voriconazole-susceptible IA cases (12/22 [54.5%] vs. 27/88 [30.7%]; P = .035), and hematology patients with IA had significantly higher mortality rates compared with solid-malignancy cases who had IA (65/217 [30%] vs. 14/78 [18%]; P = .04). Carefully designed surveillance studies linking laboratory and clinical data are required to better inform future FPPL.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/mmy/myad129

Authors


More by this author
Role:
Author
ORCID:
0000-0002-9970-9575
More by this author
Role:
Author
ORCID:
0000-0002-1808-5036
More by this author
Role:
Author
ORCID:
0000-0002-5337-1054
More by this author
Role:
Author
ORCID:
0000-0003-0875-3982
More by this author
Role:
Author
ORCID:
0000-0001-8651-4405


More from this funder
Funder identifier:
https://ror.org/01f80g185


Publisher:
Oxford University Press
Journal:
Medical Mycology More from this journal
Volume:
62
Issue:
6
Pages:
myad129
Publication date:
2024-06-01
DOI:
EISSN:
1460-2709
ISSN:
1369-3786
Pmid:
38935907


Language:
English
Keywords:
Subtype:
Review
Source identifiers:
2091711
Deposit date:
2024-07-06
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP